✨ Free AI Report
InMed Pharmaceuticals Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research InMed Pharmaceuticals Inc.
Company Research

InMed Pharmaceuticals Inc.: Business Overview, Financials & Competitive Analysis

InMed Pharmaceuticals Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Pre-revenue biotech with unique cannabinoid platform pursuing strategic M&A to advance migraine and rare disease programs. With a market cap of $7.85M and TTM revenue of $4.94M as of March 2026, InMed faces significant financial constraints typical of early-stage biotech. The company reported negative EBITDA of -$7.5M and net.

What is InMed Pharmaceuticals Inc.'s industry? InMed Pharmaceuticals Inc. (inmedpharma.com) operates in Pharmaceuticals. AskCyborg classifies InMed Pharmaceuticals Inc. under Pharmaceuticals in its company registry.

InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing small molecule drug candidates targeting CB1 and CB2 receptors for Alzheimer's, ocular, and dermatological indications. The company operates ...

3/ 10Challenged

Cyborg Score thesis

Pre-revenue biotech with unique cannabinoid platform pursuing strategic M&A to advance migraine and rare disease...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest InMed Pharmaceuticals Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for InMed Pharmaceuticals Inc.

AskCyborg analysts argue the bull and bear cases for InMed Pharmaceuticals Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
InMed Pharmaceuticals Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

InMed Pharmaceuticals Inc. Overview

Pro stress-test →

InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing small molecule drug candidates targeting CB1 and CB2 receptors for Alzheimer's, ocular, and dermatological indications. The company operates through two segments: InMed Pharmaceuticals (drug development) and BayMedica Commercial (cannabinoid manufacturing).

Strategic Profile

Pro stress-test →

Founded in 1981 and headquartered in Vancouver, Canada, InMed is positioned at the intersection of cannabinoid research and precision pharmaceuticals.

Competitive Landscape

Pro stress-test →

InMed competes in the therapeutic cannabinoids and cannabinoid-derived pharmaceuticals space alongside larger biotech firms developing CB1/CB2-targeting therapeutics. Direct competitors are limited; the company faces indirect competition from conventional drug developers in ocular, dermatological, and neurodegenerative disease markets. The merger with Migraine-focused Mentari shifts competitive positioning toward established migraine therapy markets dominated by Eli Lilly, Amgen, and others in CGRP inhibitor and other prevention classes.

Industry Context

InMed Pharmaceuticals Inc. operates in Pharmaceuticals.

Key facts

Founded: 1981 · Headquarters: Vancouver, Canada · Employees: 13-19 · Revenue: $4.94M (TTM as of March 2026) · Market cap: $7.85M

What the analysts stress-tested

The top findings that survived the multi-agent debate for InMed Pharmaceuticals Inc..

  • Market cap collapsed to $7.85M as of July 2026 despite 285% revenue growth to $4.94M TTM, indicating market skepticism of cannabinoid therapeutics viability and execution risk on clinical programs.
  • INM-755 completed Phase 2 for epidermolysis bullosa as of reporting; INM-901 patent filed for Alzheimer's treatment (September 2025), showing ongoing clinical advancement despite capital constraints and lack of approved products.

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2025Filed international patent for INM-901 in neurodegeneration/Alzheimer's treatment
  • March 2026Received Nasdaq minimum bid price compliance notification
Get alerted when InMed Pharmaceuticals Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Jazz PharmaceuticalsCannabinoid-focused pharmaceutical developer with Epidiolex commercial franchise; acquired GW Pharmaceuticals→Tilray BrandsCannabis/cannabinoid pharmaceutical company developing THC/CBD-derived therapeutics→CuraleafCannabinoid and cannabis product developer and consumer brand→Zynerba PharmaceuticalsClinical-stage biopharmaceutical company developing cannabinoid-derived therapeutics for CNS disorders→

Compare InMed Pharmaceuticals Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

InMed Pharmaceuticals Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about InMed Pharmaceuticals Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare InMed Pharmaceuticals Inc. and its top competitor on Cyborg Score”
“What did InMed Pharmaceuticals Inc. do this quarter?”
“Is InMed Pharmaceuticals Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does InMed Pharmaceuticals Inc. do?+
InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing small molecule drug candidates targeting CB1 and CB2 receptors for Alzheimer's, ocular, and dermatological indications. The company operates ...
What is InMed Pharmaceuticals Inc.'s Cyborg Score?+
InMed Pharmaceuticals Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are InMed Pharmaceuticals Inc.'s main competitors?+
Named competitors include Jazz Pharmaceuticals, Tilray Brands, Curaleaf, Zynerba Pharmaceuticals. The full competitive landscape is in the AskCyborg report.
How can I get the full InMed Pharmaceuticals Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the InMed Pharmaceuticals Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track InMed Pharmaceuticals Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.5Curaleaf Holdings, Inc.